SLC25A15 Antibody

What is SLC25A15 and why is it important in biological research?

SLC25A15 (Solute Carrier Family 25 Member 15), also known as ORC1 or ORNT1, is a mitochondrial carrier protein that catalyzes the transport of cytosolic ornithine into mitochondria in exchange for citrulline plus a proton. This exchange is electroneutral as the proton compensates for the positive charge of ornithine . SLC25A15 plays a crucial role in the urea cycle by connecting cytosolic and intramitochondrial reactions. Additionally, it can transport lysine and arginine through an antiport mechanism and catalyze an electroneutral exchange of ornithine or lysine for H+, driven by the pH gradient across the inner mitochondrial membrane .

The significance of SLC25A15 is underscored by its association with Hyperornithinemia-Hyperammonemia-Homocitrullinuria (HHH) syndrome, a rare autosomal recessive disorder caused by mutations in the SLC25A15 gene . Research on SLC25A15 contributes to our understanding of mitochondrial transport mechanisms, urea cycle disorders, and nitrogen metabolism.

What types of SLC25A15 antibodies are currently available for research?

Currently available SLC25A15 antibodies are primarily rabbit polyclonal antibodies targeting different epitopes of the protein. These include:

Most of these antibodies are unconjugated and purified using affinity purification methods . The diversity in targeting different epitopes provides researchers flexibility in experimental design based on their specific requirements.

What is the expected molecular weight of SLC25A15 on Western blots?

SLC25A15 typically appears at 30-33 kDa on Western blots, which corresponds closely to its calculated molecular weight of 33 kDa . Some variation may be observed due to post-translational modifications or differences in gel systems. When performing Western blot analysis with SLC25A15 antibodies, it's advisable to include positive control samples such as HeLa cells, mouse liver tissue, or mouse stomach tissue, which have been validated to express detectable levels of the protein .

What are the optimal conditions for Western blotting with SLC25A15 antibodies?

For optimal Western blotting results with SLC25A15 antibodies, consider the following protocol guidelines:

When troubleshooting, remember that SLC25A15 is a mitochondrial membrane protein, which may require optimization of extraction and denaturation conditions . Using fresh tissue samples and including protease inhibitors in lysis buffers is crucial for preventing degradation.

How should immunohistochemistry protocols be optimized for SLC25A15 detection?

Successful immunohistochemistry for SLC25A15 requires careful optimization:

• Antigen retrieval: TE buffer at pH 9.0 is recommended, though citrate buffer at pH 6.0 may also be effective .

• Antibody dilution: The optimal range is 1:20-1:500, with initial testing at 1:50-1:100 .

• Positive control tissues: Human liver, skin, brain, lung, and ovary tissues have been validated for SLC25A15 expression .

• Staining pattern: Expect cytoplasmic staining with potential punctate distribution, consistent with mitochondrial localization.

• Detection systems: For tissues with lower expression, consider using polymer-based or tyramide signal amplification detection systems.

For paraffin-embedded tissues, thorough deparaffinization and rehydration are essential before antigen retrieval. Endogenous peroxidase blocking (3% H₂O₂ for 10 minutes) should be performed before primary antibody incubation . Counterstaining with hematoxylin helps visualize tissue architecture while maintaining visibility of SLC25A15-specific staining.

What controls should be included when validating SLC25A15 antibodies?

A comprehensive validation strategy for SLC25A15 antibodies should include the following controls:

Additionally, using multiple antibodies targeting different epitopes of SLC25A15 and comparing their staining patterns provides robust validation . For disease-related research, including samples from HHH syndrome patients with known SLC25A15 mutations can provide valuable biological validation.

How can SLC25A15 antibodies be employed to study protein-protein interactions in mitochondrial transport?

SLC25A15 antibodies can be valuable tools for investigating protein-protein interactions through several methodologies:

• Co-immunoprecipitation (Co-IP): Use SLC25A15 antibodies to pull down the protein complex and identify interacting partners through Western blotting or mass spectrometry. For membrane proteins like SLC25A15, gentle detergents (e.g., digitonin or CHAPS) are recommended to maintain native interactions .

• Proximity Ligation Assay (PLA): This technique can detect and visualize protein interactions in situ with high sensitivity and specificity. It combines antibody recognition with DNA amplification to visualize interactions between SLC25A15 and potential partners in fixed cells or tissues.

• Immunofluorescence co-localization: Dual labeling with SLC25A15 antibodies and antibodies against potential interacting partners can provide evidence for co-localization. Super-resolution microscopy techniques enhance the resolution of co-localization studies.

• Blue Native PAGE: This technique preserves protein complexes and can be followed by Western blotting with SLC25A15 antibodies to identify the protein in native complexes.

These approaches can help identify interactions between SLC25A15 and other components of the mitochondrial transport machinery or urea cycle enzymes, providing insights into functional complexes and regulatory mechanisms .

What are effective strategies for investigating SLC25A15 mutations using antibody-based methods?

When studying SLC25A15 mutations, especially those associated with HHH syndrome, consider these antibody-based strategies:

• Epitope mapping considerations: Select antibodies whose epitopes do not overlap with mutation sites. For comprehensive analysis, use multiple antibodies targeting different regions of SLC25A15 .

• Expression analysis: Western blotting can assess whether mutations affect protein stability or expression levels. Include wild-type controls and, when possible, heterozygous samples .

• Subcellular localization studies: Immunofluorescence microscopy with co-staining for mitochondrial markers can determine if mutations alter the proper targeting of SLC25A15 to mitochondria .

• Functional correlation: Combine antibody detection with functional assays such as ornithine transport measurements to correlate protein expression with activity .

• Patient-derived materials: When available, analyze patient samples (fibroblasts, liver biopsies) to examine expression patterns of mutant SLC25A15 proteins. The table below summarizes reported mutations and their effects:

How can metabolomics approaches be integrated with SLC25A15 antibody studies?

Integrating metabolomics with SLC25A15 antibody studies creates a powerful approach to understanding this transporter's function:

• Correlation analysis: Quantify SLC25A15 protein levels in different tissues or cell types using antibody-based methods (Western blot, ELISA) and correlate with metabolite profiles, particularly ornithine, citrulline, and other urea cycle intermediates measured by mass spectrometry .

• Perturbation studies: Use SLC25A15 antibodies to confirm knockdown or overexpression efficiency in experimental models, then analyze resulting metabolic changes using targeted or untargeted metabolomics.

• Flux analysis with stable isotopes: Combine protein expression data with isotope tracing to measure dynamic flux through pathways involving SLC25A15. For example, tracking 15N-labeled ornithine conversion while monitoring SLC25A15 expression levels.

• Clinical correlations: In patient studies, particularly for HHH syndrome, combine metabolite measurements (ornithine, ammonia, homocitrulline) with SLC25A15 protein analysis in accessible samples to establish genotype-phenotype correlations .

• In situ analysis: Use immunohistochemistry to map SLC25A15 expression across tissues and correlate with metabolite distributions using mass spectrometry imaging techniques.

These integrated approaches can provide mechanistic insights into how alterations in SLC25A15 function impact metabolic pathways and contribute to disease pathophysiology .

What strategies can address weak or absent signals when using SLC25A15 antibodies?

When encountering weak or absent signals with SLC25A15 antibodies, consider these troubleshooting approaches:

• Sample preparation optimization:

  • Ensure complete protein extraction using buffers appropriate for membrane proteins (containing detergents like Triton X-100 or NP-40)

  • For mitochondrial proteins like SLC25A15, consider mitochondrial enrichment protocols

  • Use fresh samples and include protease inhibitors to prevent degradation

• Antibody optimization:

  • Try increased antibody concentration (reduce dilution ratio)

  • Extend primary antibody incubation time (overnight at 4°C)

  • Test alternative antibodies targeting different epitopes of SLC25A15

• Signal enhancement:

  • For Western blots: use more sensitive detection substrates or longer exposure times

  • For IHC/IF: implement signal amplification systems like tyramide signal amplification

  • Increase protein loading (Western blot) or tissue section thickness (IHC)

• Antigen retrieval optimization (for IHC):

  • Test both citrate buffer (pH 6.0) and TE buffer (pH 9.0)

  • Extend retrieval time or try alternative methods (microwave, pressure cooker)

• Control experiments:

  • Include positive controls known to express SLC25A15 (HeLa cells, liver tissue)

  • Verify antibody functionality using recombinant SLC25A15 protein

How can non-specific binding be minimized when using SLC25A15 antibodies?

Non-specific binding is a common challenge when working with antibodies. For SLC25A15 antibodies, consider these strategies:

• Blocking optimization:

  • Test different blocking agents (BSA, normal serum, commercial blockers)

  • Increase blocking time (2-3 hours at room temperature or overnight at 4°C)

  • Include 0.1-0.3% Triton X-100 or Tween-20 in antibody diluents

• Antibody dilution:

  • Titrate antibody to find optimal concentration that maximizes specific signal while minimizing background

  • For Western blots, dilutions of 1:500-1:2000 have been validated

  • For IHC, dilutions of 1:20-1:500 are recommended

• Washing procedures:

  • Increase number and duration of washing steps

  • Use appropriate detergent concentration in wash buffers

  • Ensure temperature consistency during wash steps

• Secondary antibody considerations:

  • Use highly cross-adsorbed secondary antibodies

  • Optimize secondary antibody concentration

  • Include negative controls omitting primary antibody

• Sample-specific treatments:

  • For tissues with high autofluorescence, incorporate treatments like Sudan Black B

  • For peroxidase-based detection, ensure thorough quenching of endogenous peroxidases

How should unexpected molecular weight bands in Western blots be interpreted?

When unexpected bands appear in Western blots using SLC25A15 antibodies, systematic analysis is required:

To distinguish between specific and non-specific bands, perform peptide competition assays where the antibody is pre-incubated with the immunizing peptide . Specific bands should disappear in this test. Additionally, using SLC25A15 knockout or knockdown samples as negative controls can help identify specific bands.

How can SLC25A15 antibodies contribute to studying HHH syndrome pathophysiology?

SLC25A15 antibodies are valuable tools for investigating the pathophysiology of HHH syndrome through several research strategies:

• Mutation-specific protein analysis: Antibodies can detect how different mutations affect SLC25A15 protein expression, stability, and localization. Recent studies have identified several mutations in different populations, including c.535C>T (p.Arg179*) and c.562_564delTTC (p.Phe188del) in Vietnamese patients, and c.44C>T (p.A15V) in Turkish patients .

• Functional correlation studies: Combining antibody detection with functional assays allows researchers to correlate protein expression with ornithine transport activity. For example, the p.A15V mutation was shown to dramatically inhibit ornithine transport despite protein expression .

• Patient sample analysis: Antibodies enable the examination of SLC25A15 expression in patient-derived materials such as fibroblasts or liver biopsies, providing direct insights into disease mechanisms.

• Model system validation: When developing cellular or animal models of HHH syndrome, antibodies confirm the knockdown or knockout efficiency and help validate the model's relevance to human disease.

• Therapeutic development: In approaches aimed at rescuing mutant protein function, antibodies can monitor changes in protein expression or stability in response to treatments such as chemical chaperones or gene therapy.

What experimental design considerations are important when studying SLC25A15 in liver metabolism?

When investigating SLC25A15 in liver metabolism, consider these experimental design elements:

• Tissue preparation and fixation: For immunohistochemistry, optimize fixation protocols to preserve mitochondrial structures while maintaining antigen accessibility. Paraformaldehyde (4%) fixation for 24 hours is typically suitable, with careful optimization of antigen retrieval methods .

• Zonal expression analysis: The liver exhibits metabolic zonation, with different metabolic activities in periportal versus pericentral regions. Use dual immunostaining with zone-specific markers to characterize SLC25A15 distribution across liver lobules.

• Nutritional state considerations: SLC25A15 function is linked to nitrogen metabolism, which varies with nutritional status. Design experiments to compare fasting versus fed states, and high versus low protein intake conditions.

• Species differences: Consider that the urea cycle activity and potentially SLC25A15 regulation may differ between species. Multiple antibodies show cross-reactivity with human, mouse, and rat samples, facilitating comparative studies .

• Pathological conditions: In liver disease models, correlate SLC25A15 expression with markers of mitochondrial function, urea cycle activity, and ammonia metabolism.

• Quantification approaches: For protein quantification, use appropriate normalization controls such as mitochondrial markers (for subcellular enrichment) or housekeeping proteins (for total lysates).

How can SLC25A15 antibodies be used in developmental studies of urea cycle maturation?

SLC25A15 antibodies offer valuable tools for studying urea cycle maturation during development:

• Temporal expression analysis: Use immunohistochemistry or Western blotting to track SLC25A15 expression across developmental stages in liver and other tissues. This can reveal when ornithine transport capacity matures relative to other urea cycle components.

• Tissue-specific expression patterns: Beyond liver, examine SLC25A15 expression in other tissues during development using immunohistochemistry. The Human Protein Atlas data suggests expression in multiple tissues including brain, thymus, thyroid, and tongue .

• Co-expression with developmental markers: Perform dual immunostaining of SLC25A15 with markers of liver maturation or bile duct development to correlate transporter expression with organ development.

• Correlation with functional acquisition: Combine protein expression data with functional measures of ornithine transport or urea production capacity at different developmental stages.

• Response to metabolic challenges: Assess how developing systems with varying levels of SLC25A15 expression respond to nitrogen loads or other metabolic challenges.

• Genetic model systems: In knockout or knockdown models, use antibodies to confirm altered expression patterns and correlate with developmental phenotypes.

These approaches can provide insights into how ornithine transport capacity develops in concert with other urea cycle components, potentially revealing critical windows for therapeutic intervention in urea cycle disorders.